NIH launches clinical study into mixed COVID-19 vaccine schedule
The National Institutes of Health yesterday announced the start of a phase 1/2 clinical trial to investigate the safety and immunogenicity of mixed boosted COVID-19 vaccination regimens. Fully-vaccinated trial participants will receive booster doses of different COVID-19 vaccines and then be followed for one year to allow for the evaluation of safety and other post-vaccination side effects. The initial trial results are expected in late summer 2021.
Related News Articles
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…